Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 p.Gly417Arg (p.G417R) ABL1 p.Gly417Arg (p.G417R)
- Associated Disease
- chronic myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2864
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1233
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Chronic Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Nilotinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 19075254
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Nilotinib | Sensitivity | true |